CAR T-Cell Therapy for Adults
CAR T-Cell Immunotherapy for Adults with Lymphoma
University Hospitals Seidman Cancer Center is offering a new cutting-edge CAR T-cell immunotherapy to fight treatment-resistant lymphoma in adult cancer patients.
CAR T-cell therapy uses the power of a patient’s own immune system to fight cancer and is FDA-approved for patients with non-Hodgkin’s diffuse large B-cell lymphoma that has relapsed or is refractory (treatment-resistant) after having at least two other kinds of treatment. This includes BREYANZI® (lisocabtagene maraleucel), which recently received FDA approval. UH Seidman Cancer Center was the first in Ohio to provide a patient with BREYANZI®.
CAR T-cell therapy is also FDA-approved for children and young adults (age 25 and under) with relapsed or refractory acute lymphoblastic leukemia (ALL).
Lymphoma in adults is usually treated with a combination of chemotherapy, radiation therapy, and/or stem cell transplant. While these treatments can be very successful in many patients, in some cases, the disease is resistant to these treatment options. In cases such as these, an immune system therapy such as CAR T-cell therapy can be an ideal treatment option.
CAR T-Cell Immunotherapy for Adults with Multiple Myeloma
UH Seidman Cancer Center was the first to provide a patient in Ohio with ABECMA® (idecabtagene vicleucel), the first CAR T-cell therapy for adults with relapsed or refractory multiple myeloma.
This CAR T-cell therapy is for the treatment of multiple myeloma in patients who have received at least four kinds of treatment regimens that have not worked or have stopped working. ABECMA® is a medicine made from your own white blood cells; the cells are genetically modified to recognize and attack your multiple myeloma cells.
What is CAR T-Cell Therapy?
CAR T-cell therapy works by taking a patient’s own white blood cells, called T-cells, and reprogramming them so that they can fight cancer cells.
After an initial procedure to remove T-cells from the patient’s blood, the blood cells are sent to a laboratory where they are genetically modified. They are then infused back into the patient’s body.
Once inside the body, the modified immune cells are better able to recognize, attack and kill the cancer cells. They become, in essence, “living drugs,” specifically programmed to destroy that patient’s unique cancer cells.
CAR T-cell immunotherapy gives new hope to leukemia, lymphoma, and multiple myeloma patients in whom other treatments have been unsuccessful.
Learn More About CAR T-Cell Therapy
If you are interested in learning more about CAR T-cell therapy please call our cancer information line at 216-844-5432.
To schedule an appointment with a physician, new patients should call 216-844-3951.